ATE336240T1 - Therapeutische verwendung von stickstoffmonoxydinhibitoren - Google Patents

Therapeutische verwendung von stickstoffmonoxydinhibitoren

Info

Publication number
ATE336240T1
ATE336240T1 AT97952182T AT97952182T ATE336240T1 AT E336240 T1 ATE336240 T1 AT E336240T1 AT 97952182 T AT97952182 T AT 97952182T AT 97952182 T AT97952182 T AT 97952182T AT E336240 T1 ATE336240 T1 AT E336240T1
Authority
AT
Austria
Prior art keywords
tissue
inhibitor
cells
population
bone marrow
Prior art date
Application number
AT97952182T
Other languages
English (en)
Inventor
Grigori Enikolopov
Natalia I Peunova
Boris Kuzin
Hollis Cline
Tatiyana Michurina
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Application granted granted Critical
Publication of ATE336240T1 publication Critical patent/ATE336240T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97952182T 1996-11-13 1997-11-13 Therapeutische verwendung von stickstoffmonoxydinhibitoren ATE336240T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3069096P 1996-11-13 1996-11-13
US4541197P 1997-05-02 1997-05-02

Publications (1)

Publication Number Publication Date
ATE336240T1 true ATE336240T1 (de) 2006-09-15

Family

ID=26706342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97952182T ATE336240T1 (de) 1996-11-13 1997-11-13 Therapeutische verwendung von stickstoffmonoxydinhibitoren

Country Status (7)

Country Link
US (2) US5977181A (de)
EP (1) EP0952828B1 (de)
AT (1) ATE336240T1 (de)
AU (1) AU5585598A (de)
CA (1) CA2271729A1 (de)
DE (1) DE69736526T2 (de)
WO (1) WO1998020865A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336240T1 (de) 1996-11-13 2006-09-15 Cold Spring Harbor Lab Therapeutische verwendung von stickstoffmonoxydinhibitoren
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US6593372B2 (en) 1996-11-13 2003-07-15 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
AU8647198A (en) * 1997-08-12 1999-03-01 Chugai Seiyaku Kabushiki Kaisha Remedies for diseases associated with bone resorption
AU3877800A (en) 1999-03-30 2000-10-16 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
JP2003500355A (ja) * 1999-05-20 2003-01-07 コールド スプリング ハーバー ラボラトリー 酸化窒素阻害剤の治療的使用
WO2003078578A2 (en) * 2002-03-12 2003-09-25 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
WO2008034929A1 (es) * 2006-09-19 2008-03-27 Fundación Progreso Y Salud Método para el cultivo y mantenimiento de células troncales pluripotenciales y de células progenitoras de mamífero en estado no diferenciado
US8470857B2 (en) * 2008-08-15 2013-06-25 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents
DK2315590T3 (da) * 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
ES2610158T3 (es) * 2008-08-15 2017-04-26 Nivalis Therapeutics, Inc. Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
EP2552947A4 (de) 2010-03-26 2013-11-13 Dartmouth College Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2013006635A1 (en) * 2011-07-05 2013-01-10 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents for liver toxicity
TWI705073B (zh) 2012-06-22 2020-09-21 達特茅斯學院基金會 新穎之vista-ig構築體及vista-ig用於治療自體免疫、過敏及發炎病症之用途
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
CN105793411B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
EP3226900A4 (de) 2014-12-05 2018-09-19 Immunext, Inc. Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
US11649283B2 (en) 2016-04-15 2023-05-16 Immunext, Inc. Anti-human vista antibodies and use thereof
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028013A1 (en) * 1993-05-20 1994-12-08 Research Corporation Technologies, Inc. Peptides for suppression of myeloid progenitor cell proliferation and treatment of septic shock
JPH07316023A (ja) * 1994-05-26 1995-12-05 Shiseido Co Ltd 育毛料
ATE336240T1 (de) 1996-11-13 2006-09-15 Cold Spring Harbor Lab Therapeutische verwendung von stickstoffmonoxydinhibitoren

Also Published As

Publication number Publication date
DE69736526D1 (de) 2006-09-28
DE69736526T2 (de) 2007-04-26
US20030119905A1 (en) 2003-06-26
WO1998020865A3 (en) 1998-07-23
EP0952828A2 (de) 1999-11-03
CA2271729A1 (en) 1998-05-22
AU5585598A (en) 1998-06-03
WO1998020865A2 (en) 1998-05-22
EP0952828B1 (de) 2006-08-16
US5977181A (en) 1999-11-02
US6809117B2 (en) 2004-10-26

Similar Documents

Publication Publication Date Title
ATE336240T1 (de) Therapeutische verwendung von stickstoffmonoxydinhibitoren
DE69721006D1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
NO20041844L (no) Peptider som er effektive i behandlingen av tumorer og andre tilstander i forbindelse med fjerning eller odeleggelse av celler
CA2265464A1 (en) Therapy for .alpha.-galactosidase a deficiency
ES551761A0 (es) Un procedimiento para la preparacion de un vector de dna recombinante
ATE219519T1 (de) Rekombinanttherapien für infektionen und hyperproliferative störungen
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
Barret et al. Outcome of scalp donor sites in 450 consecutive pediatric burn patients
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
ATE196147T1 (de) Wachstumsdifferenzierungsfaktor-12
SE8902532D0 (sv) Bestaemning av plasmaproteiner
RU94022017A (ru) Способ лечения акне или псевдофолликулита бороды, способ получения композиции, применение ингибитора фермента орнитиндекарбоксилазы для лечения акне или псевдофолликулита бороды
HUP9901188A2 (hu) Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
DE69633393D1 (de) Mitteln zur behandlung von auto-immun krankheiten
EA200001124A1 (ru) Способ генной терапии
DE69824017D1 (de) Vehikel zur gentherapie enthaltend dermales huellgewebe
DE69332373D1 (de) Menschlicher epidermaler Gen-Promotor
DE69528473D1 (de) Verwendung von hepatozyten-wachstumsfaktor zur induzierung der proliferation und differenzierung von hämatopoietischen zellen
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
PT990000E (pt) Factor 3 de crescimento do tecido conjuntivo
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
SU628904A1 (ru) Способ обезболивани
ATE251455T1 (de) Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
WO2002016419A3 (en) Progression suppressed gene 13 (psgen 13) and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties